DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care

CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today unveils an expanded portfolio at RSNA 2025, introducing next-generation imaging informatics and clinical AI solutions. The company is announcing new offerings and major enhancements across its portfolio, spanning disease detection, assessment and monitoring, remote scanning, image management and interpretation, center operations and AI orchestration—all designed to transform the imaging experience and advance population health.

“We are entering an era where AI-powered imaging can drive proactive, connected and more equitable care at global scale,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health Division, DeepHealth. “At DeepHealth, we harness AI in an integrated, end-to-end approach across our portfolio with the intent to improve healthcare delivery. By unifying clinical and operational intelligence into DeepHealth OS and deploying scalable infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency. This is how we advance our mission of empowering breakthroughs in care through imaging.”

At RSNA this year, DeepHealth showcases an expanded, integrated portfolio of AI-powered solutions that demonstrate real-world impact in addressing key healthcare challenges such as disconnected patient engagement, strained workforce, inconsistent clinical outcomes and technology, data and workflow fragmentation.

Unifying the Imaging Experience

DeepHealth connects siloed tools, teams, and workflows to automate and orchestrate key tasks in the end-to-end imaging experience. DeepHealth showcases these solutions at RSNA through its enterprise imaging and operations portfolio that includes:

Advancing Population Health with Clinical AI Solutions

DeepHealth is introducing major advancements across its Population Health & Clinical AI portfolio, supported by expanded and new FDA clearances across multiple clinical areas. These innovations are designed to help stage shift disease, drive more timely and effective screening and diagnostic pathways, and expand patient access:

At the core of this portfolio is DeepHealth OS™, a cloud-native operating system that brings together these imaging informatics and AI suites into one unified environment. The OS delivers personalized, role-based experiences with seamless access to clinical and operational data, meeting the needs of every participant in the imaging workflow. With all solutions running on one cloud-native or hybrid platform, deployment, operations, security and infrastructure management are greatly simplified for IT professionals implementing tech solutions in healthcare.

DeepHealth works with leading OEMs, cloud, AI, and platform partners to unify previously fragmented tools into a connected, end-to-end imaging experience. Elements of DeepHealth’s portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 2,000 customers and more than 5,000 radiologists leveraging its current solutions to deliver better care.

DeepHealth’s portfolio 20 is presented in scientific sessions and at Booth #1329, South Hall, Level 3 at McCormick Place in Chicago. Anchoring the space will be an Experience Theater where visitors can experience interactive, hands-on educational lectures illustrating how AI is being integrated into practice across diverse clinical and operational areas. The Theater will also feature live sessions and panel discussions with clinical collaborators, technology partners and research leaders sharing insights from real-world AI deployments and upcoming technological advancements.

Explore more about DeepHealth’s presence at RSNA 2025 and view the full schedule of live Experience Theater sessions at deephealth.com/rsna.

About DeepHealth

DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, prostate, neuro, and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. https://deephealth.com

About RadNet, Inc.

RadNet, Inc. is a leading provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 407 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has about 11,000 team members. https://radnet.com

Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the unifying clinical and operational intelligence into one system and enabling rapid-scale infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency, discussions regarding our product feature, and statements regarding our recent acquisitions. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact

Andra Axente

Director of Communications

+31614440971

andra.axente@deephealth.com

RadNet Media Contacts

Jane Mazur

SVP, Corporate Communications

+1 585-355-5978

jane.mazur@radnet.com

Mark Stolper

Executive Vice President and Chief Financial Officer

+1 310-445-2800

References